Overview

Lanreotide as Treatment of Polycystic Livers

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Radboud University
Collaborator:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin